ArticleFunctional & integrative genomics2026
MORC2 promotes acute myeloid leukemia by silencing LINE-1 retrotransposon.
Article in Functional & integrative genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Long interspersed element-1 (LINE-1 or L1) is the only autonomous transposon in humans, and its mobilization varies across cancers. The regulation of LINE-1 expression and its impact on acute myeloid leukemia (AML) remain incompletely understood. Our previous work demonstrated that LINE-1 activation prevents AML development, prompting us to explore how LINE-1 repressors affect AML. Here we constructed a four-gene signature (LINE-1 repressors index, LRI) that effectively stratifies risk in AML patients. Further analysis identified microrchidia family CW-type zinc finger 2 (MORC2) as a key predictor of AML clinical outcomes within the LRI genes. MORC2 depletion significantly impairs leukemia cell proliferation, reduces tumor burden and attenuates AML progression. Mechanistically, MORC2 restricts LINE-1 activity in leukemia cells. Downregulation of MORC2 increases LINE-1 expression and retrotransposition, which in turn accumulates DNA damage and compromises the genomic stability required for leukemia cell proliferation. Collectively, these observations suggest that targeted inhibition of MORC2 to activate LINE-1 may represent a new therapeutic strategy for AML.
Indexed as
Identifiers
41721893What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.